Related Experiment Video
Updated: Jul 8, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.5K
Sarcopenia is a negative prognostic factor in localized extremities/trunk wall soft tissue sarcomas
Tiziana Robba1, Vito Chianca2, Martina Rabino3
1Radiologia, Ospedale CTO, AOU Città della Salute e della Scienza di Torino, Italy.
Summary
Sarcopenia negatively impacts survival and increases complications in extremities and trunk wall soft tissue sarcoma (ESTS) patients. This study highlights sarcopenia as a crucial prognostic factor in ESTS outcomes.
Area of Science:
- Oncology
- Radiology
- Geriatrics
Background:
- Sarcopenia, a loss of skeletal muscle mass and function, is an emerging prognostic determinant in cancer patients.
- Limited data exist on sarcopenia's impact in extremities and trunk wall soft tissue sarcomas (ESTS).
Purpose of the Study:
- To evaluate the impact of sarcopenia on the prognosis and outcomes of patients with ESTS.
Main Methods:
- Utilized SliceOMatic software to measure skeletal muscle area (SMA), subcutaneous fat area (SFA), and visceral fat area (VFA) from CT scans.
- Calculated skeletal mass index (SMI) and muscle density (MD).
- Correlated these parameters with post-surgical complications and survival using Kaplan-Meier analysis.
Main Results:
- Overall survival was significantly worse for sarcopenic patients (low SMI and low MD).
- Sarcopenic patients exhibited a trend towards increased post-surgical complications (30.5% vs 17.0%).
- Sarcopenia prevalence was not significantly higher in older patients or based on other prognostic factors.
Conclusions:
- Sarcopenia appears to be a negative prognostic factor in ESTS patients.
- Further investigation into sarcopenia's role in ESTS is warranted.
- Sarcopenia assessment may aid in risk stratification and treatment planning for ESTS patients.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...